The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this article, we are going to take a look at where Summit Therapeutics (NASDAQ:SMMT) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception.

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Summit Therapeutics (NASDAQ:SMMT) stands against the other stocks ...

Summit Therapeutics Inc. (NASDAQ:SMMT) has disclosed recent executive compensation adjustments and a financial update in its latest SEC filing on January 24, 2025. The biopharmaceutical company ...

EXCLUSIVE: The long-awaited film adaptation of Erik Larson’s bestselling book The Devil in the White City just got a shot of adrenaline, as sources tell Deadline that 20th Century has come on to ...

Summit Therapeutics has a 12 month low of $2.10 and a 12 month high of $33.89. Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th.

spurred on most by the presentation of promising clinical data from Summit Therapeutics. In September, the company presented data showing its PD-1 and VEGF bispecific outperformed Keytruda in a ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

On Tuesday, Summit Therapeutics plc (NASDAQ:SMMT) shares, currently trading at $19.03, maintained its Buy rating and $44.00 price target from H.C. Wainwright, following a recent engagement with the ...